ABL Bio Inc. (KOSDAQ:298380)

ABL Bio Statistics

Total Valuation

ABL Bio has a market cap or net worth of KRW 10.67 trillion. The enterprise value is 10.61 trillion.

Market Cap	10.67T
Enterprise Value	10.61T

Important Dates

The next estimated earnings date is Thursday, March 26, 2026.

Earnings Date	Mar 26, 2026
Ex-Dividend Date	n/a

Share Statistics

ABL Bio has 55.99 million shares outstanding. The number of shares has increased by 7.23% in one year.

Current Share Class	55.99M
Shares Outstanding	55.99M
Shares Change (YoY)	+7.23%
Shares Change (QoQ)	+2.42%
Owned by Insiders (%)	25.75%
Owned by Institutions (%)	15.24%
Float	41.57M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	134.41
PB Ratio	68.07
P/TBV Ratio	70.24
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-280.59
EV / Sales	133.69
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-173.00

Financial Position

The company has a current ratio of 1.43, with a Debt / Equity ratio of 0.35.

Current Ratio	1.43
Quick Ratio	1.41
Debt / Equity	0.35
Debt / EBITDA	n/a
Debt / FCF	-0.90
Interest Coverage	-40.67

Financial Efficiency

Return on equity (ROE) is -23.38% and return on invested capital (ROIC) is -11.94%.

Return on Equity (ROE)	-23.38%
Return on Assets (ROA)	-9.84%
Return on Invested Capital (ROIC)	-11.94%
Return on Capital Employed (ROCE)	-25.65%
Weighted Average Cost of Capital (WACC)	6.83%
Revenue Per Employee	777.94M
Profits Per Employee	-370.65M
Employee Count	102
Asset Turnover	0.31
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +369.79% in the last 52 weeks. The beta is 0.47, so ABL Bio's price volatility has been lower than the market average.

Beta (5Y)	0.47
52-Week Price Change	+369.79%
50-Day Moving Average	194,876.00
200-Day Moving Average	130,179.00
Relative Strength Index (RSI)	50.93
Average Volume (20 Days)	650,204

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ABL Bio had revenue of KRW 79.35 billion and -37.81 billion in losses. Loss per share was -734.00.

Revenue	79.35B
Gross Profit	79.23B
Operating Income	-40.39B
Pretax Income	-37.88B
Net Income	-37.81B
EBITDA	-36.94B
EBIT	-40.39B
Loss Per Share	-734.00

Balance Sheet

The company has 114.94 billion in cash and 55.33 billion in debt, with a net cash position of 59.62 billion or 1,064.85 per share.

Cash & Cash Equivalents	114.94B
Total Debt	55.33B
Net Cash	59.62B
Net Cash Per Share	1,064.85
Equity (Book Value)	156.70B
Book Value Per Share	2,806.69
Working Capital	52.55B

Cash Flow

In the last 12 months, operating cash flow was -41.25 billion and capital expenditures -20.07 billion, giving a free cash flow of -61.32 billion.

Operating Cash Flow	-41.25B
Capital Expenditures	-20.07B
Depreciation & Amortization	3.45B
Net Borrowing	11.32B
Free Cash Flow	-61.32B
FCF Per Share	-1,095.21

Margins

Gross margin is 99.85%, with operating and profit margins of -50.90% and -47.65%.

Gross Margin	99.85%
Operating Margin	-50.90%
Pretax Margin	-47.73%
Profit Margin	-47.65%
EBITDA Margin	-46.55%
EBIT Margin	-50.90%
FCF Margin	n/a

Dividends & Yields

ABL Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.23%
Shareholder Yield	-7.23%
Earnings Yield	-0.35%
FCF Yield	-0.57%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ABL Bio has an Altman Z-Score of 19 and a Piotroski F-Score of 2.

Altman Z-Score	19
Piotroski F-Score	2